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Background: Although long-term estrogen (E2) exposure is associated with increased breast cancer (BC) risk, and E2
appears to sustain growth of BC cells that express functional estrogen receptors (ERs), its role in promoting BC stem
cells (CSCs) remains unclear. Considering that Gli1, part of the Sonic hedgehog (Shh) developmental pathway, has
been shown to mediate CSCs, we investigated whether E2 and Gli1 could promote CSCs and epithelial-mesenchymal
transition (EMT) in ER+ BC cell lines.
Methods: We knocked down Gli1 in several BC cells using a doxycycline-controlled vector, and compared Gli1-knockdown
cells and Gli1+ cells in behavior and expression of ER, Gli1, ALDH1 (BC-CSC marker), Shh, Ptch1 (Shh receptor)
and SOX2, Nanog and Bmi-1 (CSC-associated transcriptions factors), using PCR; tissue microarrays, western blot;
chromatin immunoprecipitation q-PCR, confocal immunofluorescence microscopy; fluorescence-activated cell
sorting; annexin–flow cytometry (for apoptosis); mammosphere culture; and colony formation, immunohistochemistry,
Matrigel and wound-scratch assays.
Results: Both mRNA and protein expressions of ER correlated with those of Gli1 and ALDH1. E2 induced Gli1
expression only in ER+ BC cells. E2 promoted CSC renewal, invasiveness and EMT in ER+/Gli1+ cells but not in
Gli1-knockdown cells.
Conclusions: Our results indicate that estrogen acts via Gli1 to promote CSC development and EMT in ER+ BC cells.
These findings also imply that Gli1 mediates cancer stem cells, and thus could be a target of a novel treatment for
ER+ breast cancer.
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Serial studies have suggested that breast cancer stem cells
(CSCs) play critical roles in tumor growth, invasion, me-
tastasis and resistance to cytotoxic agents and radiation
[1]. CSCs, like other stem cells, have unique charac-
teristics, such as the ability to self-renew, generate dif-
ferentiated cells [2] and express key stemness-associated
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reproduction in any medium, provided the or[3-5]. In human breast cancer, CSCs also appear to
be enriched within cell subpopulations with a CD44+/
CD24−/low surface marker profile or with high intracellular
aldehyde dehydrogenase 1 (ALDH1) activity [6-8]. How-
ever, the molecular mechanisms regulating breast CSC
frequency, localization and maintenance remain poorly
understood.
Epithelial-mesenchymal transition (EMT) is a process
that involves epithelial cells acquiring a mesenchymal
phenotype and migratory capability and plays an impor-
tant role in tumor metastasis [9,10]. Importantly, the
EMT process has been shown to be associated with the
acquisition of stem cell properties in normal and cancer
cells [11,12]. This crucial event results from transcrip-
tional repression of E-cadherin through overexpression. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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vimentin and Bmi-1 [5,13]. The link between EMT and
CSCs enables cancer cells to migrate from the primary
tumor and colonize at distant sites.
Estrogen is vital for normal postpubertal mammary
development and long-term exposure to estrogens is
proven to be associated with an increased risk of breast
cancer. Although abundant evidence has suggested that
estrogen sustains the growth of breast cancer cells ex-
pressing functional estrogen receptors (ERs) [14], the
role of estrogen in promoting breast CSCs remains con-
troversial. Some researchers think that ER-positive cells
contribute to the stem cell compartment directly sti-
mulated by hormones [15,16], while others consider that
estrogen may stimulate the expansion of a specific stem
cell compartment in a paracrine manner [17-19]. Similar
to the dynamic spatio-temporal signaling that governs
the specification and maintenance of normal mammary
gland stem cells [18,20], specific hormone-growth factor
paracrine signaling pathways have also proven to regu-
late stem-like breast cancer cells [17,18].
Sonic hedgehog (Shh)/Gli signaling controls a variety
of developmental processes, such as pattern formation,
differentiation, proliferation and organogenesis. The net
effect of pathway stimulation by Shh protein binding to
the protein patched homolog 1 receptor (Ptch1) is the
activation of members of the Gli family of zinc finger
transcription factors, which translate the extracellular
Shh stimulus into defined transcriptional programs in a
context-dependent and cell type-specific manner [21].
Gli1, a member of the Gli family, was originally identi-
fied as an amplified gene in malignant glioma [22] and
was proven to be able to regulate stem cells and cancer
stem cells [23]. Moreover, Gli1 can be expressed without
active Shh signaling [24]. However, whether Gli1 is in-
volved in estrogen-induced stemness and invasiveness in
breast cancer remains uninvestigated.
In this study, we investigated whether estrogen could
promote CSC maintenance and EMT through Gli1 in
human ER-positive breast cancer cell lines MCF-7 and
HCC1428, and ER-negative cell lines BT549 and MDA-
MB-231. Here, we provide direct evidence that estrogen
promoted the acquisition of the CSC phenotype and
EMT through transcriptional activation of Gli1 only in
ER-positive breast cancer cells.
Results
ER expression is positively correlated with Gli1 and
ALDH1 in human breast cancer cell lines
We examined the endogenous mRNA expression of breast
cancer stem cell markers ALDH1, Gli1 and ER in several
human breast cancer cell lines using real-time polymerase
chain reaction (PCR; Figure 1A–C). Our data showed that
ALDH1 and Gli1 mRNAs were detectable in all cell lines.We then used linear correlation analysis to evaluate the re-
lationship among Gli1, ALDH1 and ER expression levels.
We found that ER expression positively correlated with
Gli1 and ALDH1 (Figure 1D & E). Next, we examined the
expression of the ER protein using western blotting and
immunofluorescence assays in MCF-7, HCC1428, MDA-
MB-231 and BT549 cells. As shown in Figure 2A–C, ER
expression was higher in MCF-7 and HCC1428 cells and
barely detectable in MDA-MB-231 and BT549 cells.
Estrogen-induced Gli1 expression only in ER-positive
breast cancer cells
Because ER expression was correlated with Gli1, we
then asked whether estrogen could influence Shh pathway
activation in breast cancer cells. MCF-7, HCC1428,
MDA-MB-231 and BT549 cells were incubated with 10
nM estrogen (E2) with or without 1 μM 4-hydroxy tamo-
xifen (4OHT) for 4 days, after which Shh and Gli1 protein
and mRNA expression were measured. In ER-positive
MCF-7 and HCC1428 cells, Gli1 expression was signifi-
cantly increased in estrogen-treated cells compared with
that in control (ETOH-treated) cells. Additionally, 4OHT
inhibited estrogen-induced expression of Gli1 (Figure 3A,
B & Additional file 1: Figure S1A). However, E2 failed to
significantly increase Gli1 expression in ER-negative MDA-
MB-231 and BT549 cells (Figure 3C, D & Additional file 1:
Figure S1B). Shh expression was not affected in any of the
four cell lines tested. Our results indicated that estrogen
activated the Shh/Gli1 pathway only in ER-positive breast
cancer cells through noncanonical Shh signaling.
To elucidate the mechanism by which E2 activated the
Shh/Gli1 pathway, we tested cyclopamine, a canonical
inhibitor of Smo, in the Shh signaling pathway. Cyclo-
pamine plus E2 were incubated with MCF-7 cells for
4 days. We then analyzed and compared Gli1 protein
and mRNA expression levels in ETOH and E2-treated
cells. Cyclopamine did not inhibit estrogen-induced acti-
vation of Gli1 (Figure 3E & F).
We also treated breast cancer cells with the Shh ligand
to examine the effect of Shh on Gli1 and Ptch1 mRNA
expression. Addition of various concentrations of Shh to
these cells for 24 h increased both Gli1 and Ptch1 mRNA
expression levels relative to untreated cells (Additional
file 2: Figure S2). These results indicated that Gli1 acti-
vation was not mediated by canonical Shh signaling.
Given that E2 modulated Gli1 transcription, quanti-
tative chromatin immunoprecipitation (qChIP) assays
were performed in ETOH and E2-treated MCF7 cells to
determine the mechanism of this E2 effect. We found
increased ER protein binding to the Gli1 promoter
(area #1), as well as to the Gli1 gene body (area #3) in
E2-treated MCF7 cells compared with ETOH-treated
control cells (Figure 3H). The occupancy of IgG at the
Gli1 gene promoter was not changed by E2 treatment
Figure 1 Endogenous expression of ER, Gli1 and ALDH1 in human breast cancer cells lines. MRNA levels of (A) ER, (B) Gli1 and (C) ALDH1
were measured using real-time RT-PCR. (D & E) Linear correlation assays were used to analyze the relationship between ER and Gli1 (D) or ER
and ALDH1 (E) expression levels.
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transcriptional activation of Gli1, probably through
enriching ER occupancy at the Gli1 gene promoter and
gene body.Estrogen-induced CSC survival and self-renewal in
ER-positive breast cancer cells is mediated by Gli1
To determine whether Gli1 mediated E2-induced stem-
ness and invasiveness in breast cancer cell lines, MCF-7
Figure 2 ER expression in MCF-7, HCC1428, MDA-MB-231 and BT549 cells. (A) ER protein levels were analyzed using western blotting.
β-Actin levels were measured as a loading control. (B) Histograms illustrate ER protein expression relative to that of β-actin. All data corresponded
to the mean ± SD of three independent experiments. (C) Immunofluorescence staining of ER in MCF-7, HCC1428, MDA-MB-231 and BT549 cells.
Green represents ER staining. Blue signals represent nuclear DNA staining with DAPI. Scale bars indicate 25 μm.
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tors carrying short hairpin RNA (shRNA) targeting Gli1.
Cells were grown in the absence (shVEC transfected
cells) or presence (shGli1-1 and shGli1-2 transfected
cells) of Dox for 4 days. They were then harvested and
analyzed using western blotting. As shown in Figure 4A
and Additional file 1: Figure S1C, Gli1 protein levels in
shGli1-1 and shGli1-2 cells were significantly reduced
when compared with those of the control (shVEC).
Cells were then transfected with shVEC, shGli1-1 or
shGli1-2 (the latter two representing Gli1-knockdown
cells) and treated with E2 for 4 days, following which the
CD44+/CD24–/low cell population was observed using
flow cytometry. We found that treatment of shVEC cells
with E2 induced a statistically significant expansion of
CD44+/CD24–/low stem-like cells. In Gli1-knockdowncells, E2 failed to significantly increase the proportion of
CD44+/CD24–/low cells (Figure 4B, C and Additional
file 1: Figure S1D & E). The parallel expression patterns of
Gli1 and CSC markers indicated that Gli1 may regulate
the expansion of CSCs in estrogen-treated ER-positive
breast cancer cells (Figure 4A–C & Additional file 1:
Figure S1C–E).
Next, shVEC and Gli1-knockdown cells were cultured at
very low densities (1 cell/μL) in 96-well plates containing
serum-free medium with or without E2 for seven days.
In the presence of E2, shVEC cells produced more and
larger spheres compared with control cells (p < 0.01;
Figure 4D–F). In Gli1-knockdown cells, E2 failed to sig-
nificantly increase the number and size of these spheres
(p < 0.01; Figure 4D–F). The significant inhibition in Gli1-
knockdown cells of the estrogen-mediated increase in
Figure 3 Estrogen promoted the expression of Gli1 through noncanonical Shh signaling in MCF-7 cell lines. (A & C) Western blotting was
used to detect (A) Gli1 and Shh expression in MCF-7 or (C) MDA-MB-231 cells incubated with 10 nM estrogen (E2) with or without 1 μM 4-hydroxy
tamoxifen (4OHT) for 4 days. β-Actin was used as a loading control. In (B) MCF-7 or (D) MDA-MB-231 cells, mRNA expression levels of Gli1 and Shh
were measured using qRT-PCR, and expression was normalized to that of GAPDH. (E) Western blotting was used to detect Gli1 protein expression
in E2 and/or cyclopamine-treated MCF7 cells. (F) RT-PCR was used to detect Gli1 mRNA expression in E2 and/or cyclopamine-treated MCF7 cells.
(G) Schematic presentation of three regions relative to the Gli1 transcriptional start site used to design primers to test for ER-α occupied abundance.
(H) QChIP was performed to assess ER-α occupancy in ETOH and E2-treated MCF7 cells. (I) IgG was used as negative control. “% of input” indicates the
ratio of DNA fragment of each promoter region bound by ER-α to the total amount of input DNA fragment without ER-α antibody pull-down. All data
correspond to the mean ± SD of three independent experiments. **, ## indicate significant differences from the control (p < 0.001).
Sun et al. Molecular Cancer 2014, 13:137 Page 5 of 16
http://www.molecular-cancer.com/content/13/1/137sphere formation suggested that Gli1 was indeed involved
in the regulation of estrogen-induced self-renewal of breast
CSCs.
The proliferative potential of these breast cells under
the same conditions were also assessed using a colonyformation assay. We observed that shVEC cells showed a
significant increase in the number and size of colonies in
the presence of E2. However, E2-induced proliferation was
not observed in Gli1-knockdown cells (Figure 5A–C).
Flow cytometric analyses of apoptosis and cell cycle
Figure 4 (See legend on next page.)
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Figure 4 Knockdown of Gli1 in ER-positive breast cancer cells inhibited estrogen induced sphere formation and CD44+/CD24-/low cells.
(A) MCF-7 cells were transfected with control shRNA (shVEC) or shGli1 (shGli1-1 or shGli1-2) in the absence or presence of E2. Gli1 protein levels
were analyzed using western blotting. β-Actin levels were measured as a loading control. (B) MCF-7 cells were treated with 10 nM E2 or ETOH as
a control and transfected with shGli1-1, shGli1-2 or shVEC. After 4 days, cells were stained with anti-CD44-APC and anti-CD24-PE antibodies, and
CD44+/CD24-/low subpopulations were examined using flow cytometry. (C) Histograms illustrate percentages of CD44+/CD24-/low subpopulations.
(D) Representative images of MCF-7 and HCC1428 cells in the absence or presence of E2. MCF-7 and HCC1428 cells (1 cell/μL) were cultured in
96-well plates containing 100 μL SFM in each well with or without E2 for seven days. (E & F) The number of spheres was counted under a microscope.
Error bars represent SEMs. **, ## indicate significant differences from the control (p < 0.001).
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induced ER-positive breast cancer cell survival and pro-
liferation (Additional file 3: Figure S3).
To further investigate the mechanism through which
Gli1 regulated CSCs, MCF7 cells were treated with E2 (0–
10 nM) for 4 days. Gli1, Shh, ALDH1, Nanog, SOX2 and
Bmi-1 expression levels were measured using real-timeFigure 5 Estrogen increased the proliferation of ER-positive breast ca
MCF-7 and HCC1428 cells were transfected with vehicle control shRNA (shVEC
number of colonies was counted under a microscope. Error bars represent thPCR and western blotting. As shown in Figure 6A and B,
Gli1, ALDH1, Nanog, SOX2 and Bmi-1 expression levels
all gradually increased with increasing E2 concentrations,
whereas Shh was virtually unchanged. The expression of
CSC markers was also measured following transfection of
MCF-7 cells with shVEC or Gli1-knockdown constructs
and subsequent treatment with E2. As expected, ALDH1,ncer cells. (A) Colony formation assays in MCF-7 and HCC1428 cells.
), shGli1-1 or shGli1-2 in the absence or presence of E2. (B & C) The
e SEM. **, ## indicate significant differences from the control (p < 0.001).
Figure 6 E2 enhanced the expression of CSC markers in ER-positive MCF-7 cells through Gli1. (A) MCF7 cells were treated with various
concentrations (0.1, 1 or 10 nM) of E2 for 4 days. MRNA expression levels of Gli1, Shh, ALDH1, Nanog, SOX2 and Bmi-1 were measured using qRT-PCR,
and expression was normalized to that of GAPDH. (B) Western blotting was used to determine the effects of various concentrations of E2 on the
expression of Gli1, Shh, ALDH1, Nanog, SOX2 and Bmi-1 proteins in MCF-7 cells. β-Actin was used as a loading control. (C) MCF-7 cells were
transfected with vehicle control shRNA (shVEC), shGli1-1 or shGli1-2 and grown in medium with ETOH or E2 for 4 days. RNAs were extracted
and assayed using qRT-PCR to determine the expression levels of ALDH1, Nanog, SOX2 and Bmi-1 mRNAs. Bars represent the means ± SEs of
three experiments (**, ##: P < 0.01). (D) Effects of E2 on the expression of ALDH1, Nanog, SOX2 and Bmi-1 were estimated using western
blotting. β-Actin was used as a loading control.
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cantly enhanced in shVEC cells after E2 treatment, but
remained unchanged in Gli1-knockdown cells following
E2 treatment (Figure 6C & D). Because E2 simul-
taneously induced CSC-related gene expression and
Gli1 activation without affecting Shh expression, these
results implied that E2 induced the expansion of breast
CSCs through a noncanonical ligand-independent Shh/
Gli signaling pathway.Estrogen-induced EMT in breast cancer cells is mediated
by Gli1
Recent data has indicated that cancer cells often undergo
EMT during cancer metastasis, which results in a mesen-
chymal fibroblast-like morphology, reduced intercellular
adhesion, increased motility and increased invasive and
migratory properties [25]. EMT-type tumor cells are
closely associated with tumor recurrence and therapeutic
resistance and display several characteristics of CSCs [26].
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cancer cells exhibited Gli1-dependent changes in cell
motility using a wound healing assay in MCF-7 and
HCC1428 cells. An area devoid of cells was created at
time 0 h by scraping the monolayer of shVEC-transfected
and Gli1-knockdown cells, followed by incubation of
the cells with ETOH or E2 for 48 h. Compared with
Gli1-knockdown cells, estrogen-treated shVEC-transfected
MCF-7 and HCC1428 cells showed a significantly higher
rate of migration (p < 0.01), and the leading edges along
the scraped areas had almost coalesced 48 h after scraping
(Figure 7A, B and Additional file 4: Figure S4A & B). A
Matrigel invasion assay was also performed. The results
showed that the number of E2-treated shVEC-transfected
cells that migrated across both the Matrigel and the insert
were 3.23 and 1.97 times higher than those of ETOH-
treated MCF-7 and HCC1428 cells, respectively (Figure 7C,
D and Additional file 4: Figure S4C & D). In Gli1-
knockdown cells, E2 failed to alter the number of migrated
or invaded cells. These data indicated that Gli1 played a
significant role in mediating the invasiveness of ER-positive
breast cancer cells.
Next, we examined the impact of Gli1 knockdown on
estrogen-induced EMT. As shown in Figure 8A, MCF-7
cells transfected with shGli1-1 and shGli1-2 exhibited an
epithelial phenotype in the presence of E2, similar to that
displayed by MCF-7 cells in the absence of E2, regardless
of whether they were transfected with shGli1-1, shGli1-2
or shVEC. In contrast, MCF-7 cells transfected with
shVEC displayed a spindle-shaped morphology after E2
stimulation. This morphological transformation was con-
sistent with the reduction in E-cadherin expression
and increase in vimentin expression in estrogen-treated
shVEC-transfected cells (Figure 8B & C). In Gli1-knock-
down cells, Gli1 knockdown partly reversed E2-induced
expression of E-cadherin and vimentin, as shown using
real-time PCR and western blot analysis (Figure 8B & C).
This observation was consistent with the notion that Gli1
may be responsible for the estrogen-induced EMT in
ER-positive breast cancer cells.
Correlation of ER, Gli1 and ALDH1 expression in human
breast cancer tissues
To determine whether there were any correlations among
ER, Gli1 and the CSC marker ALDH1 in breast cancer
specimens, we used a tissue microarray containing 100
breast cancer samples and 10 adjacent normal breast tis-
sue or adenosis samples to analyze the expression of ER,
Gli1 and ALDH1 using immunohistochemical staining.
Gli1 and ALDH1 protein expression levels were low or
undetectable in the 10 normal samples (data not shown)
but comparatively high in breast tumor tissues (Figure 9A).
Moreover, ER expression was positively correlated with
Gli1 and ALDH1 expression levels (Figure 9B).Discussion
The incidence of breast cancer is increasing worldwide,
and breast cancer is quickly becoming one of the most
serious diseases for women today. Currently, treatments
for breast cancer mainly include chemotherapy, surgery,
endocrine and radiation therapies. However, metastases
and recurrences have become the major bottlenecks in all
of these treatment options. The CSC hypothesis has shed
new light on the development of resistance to therapy,
proposing that a pool of malignant cells with stem cell-
like properties exists and that this pool of malignant cells
increases the capacity for resistance to common che-
motherapeutic treatments as compared with their more
differentiated nontumorigenic counterparts; these CSCs
are therefore thought to be responsible for tumor recur-
rence after treatment [9]. Thus, therapeutic strategies that
specifically target breast CSCs can be effective in era-
dicating tumors and reducing the risk of relapse and
metastasis.
Estrogens are essential mitogens for normal mammary
epithelial cells, and prolonged exposure to estrogen is
considered an important risk factor for breast cancer de-
velopment. Although 60–70% of human breast cancers
are ER-positive [27] and respond to anti-estrogen therapy,
many of them will inevitably progress to the estrogen-
independent stage and develop resistance to anti-estrogen
therapy [14]. The existence of CSCs offers a simple ex-
planation as to the presence of endocrine resistance in
breast cancer [28-30]. There have been conflicting reports
about the effects of estrogen on breast CSCs; some studies
have reported that estrogen can increase or decrease CSC
numbers in breast cancer cell lines [18,31]. Here, we iden-
tified estrogen as an important positive modulator of CSC
properties in ER-positive breast cancer cell lines.
Emerging studies have demonstrated that CSC-enriched
populations exhibit low/no expression of ER in ER-posi-
tive cell lines [17,18,32], suggesting that the effects of
estrogen on breast CSCs are not direct. Our data de-
scribed here demonstrated that breast CSC activity and
cell surface marker expression were increased by estrogen
exposure through its effects on the estrogen/Gli1-sig-
naling axis. We found that estrogen induced transcrip-
tional activation of Gli1 through enriching ER occupancy
at the Gli1 gene promoter and gene body. It may repre-
sent a novel mechanism underlying this phenomenon,
which we will try to address in future studies. Moreover,
because cyclopamine inhibited Smo, which is a critical
component of the canonical pathway, but did not inhibit
the expression of Gli1, our current data strongly suggested
the involvement of a noncanonical pathway.
EMT, a process through which epithelial cells acquire
characteristics of mesenchymal cells, is thought to play
an important role in invasion and metastasis [33] and is
closely associated with the “stemness” of cancer cells
Figure 7 (See legend on next page.)
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Figure 7 E2 enhanced the invasiveness of MCF-7 cells via Gli1. (A) Representative images of wounds at 0 and 48 h in the presence of ETOH
or E2. (B) Histograms illustrate relative wound widths at 0 and 48 h. The migration distance of each cell was measured after the photographs
were converted to Photoshop files. (C) Matrigel invasion assay. MCF-7 cells were seeded into Matrigel-coated invasion chambers and were treated
with ETOH (control) or E2 for 48 h. Representative images of stained invaded cells are shown. Magnification 100×. (D) The number of migrated
cells was quantified by counting cells from 10 random fields. Data are representative of three independent experiments. Bars represent the
means ± SEs of three experiments (**, ##: P < 0.01).
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duced cellular morphological changes in breast cancer
cells, consistent with the acquisition of the EMT pheno-
type, as characterized by the upregulation of vimentin
and downregulation of E-cadherin expression. EMT was
significantly decreased when Gli1 was knocked down,
and this was associated with reduced CSC numbers, as
indicated in the mammosphere assay, and accompanied
by decreased expression of Gli1. These data indicated
that Gli1 mediated the estrogen-induced EMT in ER-
positive breast cancer cells.
ER-negative tumors, especially triple-negative breast
cancer (TNBC), are more aggressive and tend to harbor
more CSCs [35]. While much of our data were collected
using the ER-positive MCF7 and HCC1428 cell lines,
we were able to observe upregulation of Gli1 in manyFigure 8 Knockdown of Gli1 inhibited estrogen-induced EMT in MCF-
a fibroblast-like appearance in shVEC-transfected MCF-7 cells. Gli1-knockdown
seven days after treatment with E2. Scale bar,200 μm. ShVEC, shGli1-1 and shG
the presence ETOH or E2 for seven days. (B) Real-time qRT-PCR was used to d
represent the means ± SEs of three experiments (**, ##: P < 0.01). (C) Western b
level of E-cadherin and vimentin proteins. β-Actin was used as a loading contrdifferent primary human tumor tissue samples (Figure 1B),
suggesting the relevance of this pathway in primary
tumors. Our results showed that the expression levels of
Shh and Gli1 were both high in MDA-MB-231 and
BT549 cells; however, the expression of these targets was
not affected by estrogen. Goel et al. showed that a novel
autocrine pathway involving vascular endothelial growth
factor (VEGF)/VEGF receptor neuropilin-2 (NRP2), α6β1
and Gli1 contributed to the initiation of TNBC and de-
monstrated that Gli1 was activated in noncanonical Shh
signaling [35]. Additionally, DiMeo et al. provided evidence
of a molecular link between Wnt signaling, self-renewal,
EMTand metastasis in basal-like breast cancers [36].
Taken together, the data presented in our study pro-
vided evidence that Shh signaling pathway components
were widely expressed in breast cancer. Estrogen had the7 cells. (A) Estrogen induced morphological change from an epithelial to
cells (shGli1-1 and shGli1-2) still maintained their epithelial morphologies
li1-2-transfected MCF-7 cells were cultured in medium with 1% FBS in
etermine the expression levels of E-cadherin and vimentin mRNAs. Bars
lotting was used to determine the effects of shGli1 on the expression
ol.
Figure 9 The expression of ER correlated with the expression of EMT and stem cell-related markers in breast cancer tissue. (A) Expression
levels of ER, Gli1 and ALDH1 were measured in a breast cancer tissue microarray using immunohistochemistry. Final magnification, 40×. Scale bar,
50 μm. (B) ER expression was significantly correlated with Gli1 and ALDH1 expression in breast cancer tissues. The coordinate axis equals the
percentage of positive cells relative to the total number of cancer cells.
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ding to the Gli1 promoter in ER-positive breast cancer
in vitro. It will be important to also test whether these
results can be translated in animal studies. A critical pro-
perty of CSCs is their ability to repopulate heterogeneous
tumor populations and to functionally demonstrate
tumor-initiating capacity in vivo. There is significant inter-
est in understanding the biology behind solid tumor stem
cells and identifying drug targets and therapeutic ap-
proaches for eliminating these tumor subpopulations.Conclusion
CSC self-renewal and EMT enable tumor metastasis, a
key driving force for tumor growth and recurrence. Estro-
gen is a steroid hormone that has been closely linked to
enhanced growth and invasion of breast cancer. Using
breast cancer cells lines (MCF-7 and HCC1428), we de-
monstrated that estrogen may act via Gli1 to promote
CSC development and EMT in ER-positive breast cancer
cells, which may contribute to breast tumor malignancy.
Thus, Gli1, which promotes the expansion of cancer stem
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http://www.molecular-cancer.com/content/13/1/137cells, may be a potential therapeutic target for novel treat-
ments for ER-positive breast cancer.
Methods
Chemicals and antibodies
Lipofectamine 2000 transfection reagent and TRIzol LS
Reagent were purchased from Invitrogen (Grand Island,
NY, USA). The DAB substrate kit for peroxidase was pur-
chased from Vector Laboratories, Inc. (Burlingame, CA,
USA). Antibodies against Gli1, ERα, E-cadherin, Vimentin,
Nanog, Bmi-1, SOX2, Smo and β-actin were from Cell
Signaling Technology (Danvers, MA, USA). Anti-ALDH
antibodies were from BD (Franklin Lakes, NJ, USA). Anti-
Shh antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Amino-terminal Shh (ShhN) pep-
tide was from R&D Systems (Minneapolis, MN, USA).
Unless otherwise noted, all other chemicals were from
Sigma (St. Louis, MO, USA).
Cell culture
All the human breast cancer cell lines were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). HCC1428, MDA-MB-231, BT549,
HCC1937, HCC1569, HCC70, HCC1500, HS578T, SK-
BR-3, AU565 and ZR-75-1 cells were grown in RPMI
1640 medium supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. MCF-7, T47D,
BT474, BT483, MDA-MB-468, MDA-MB-453, MDA-
MB-435 and MDA-MB-361 cells were grown in DMEM
medium supplemented with 10% FBS and 1% penicillin/
streptomycin. MCF-10A cells were cultured in DMEM/
F12 supplemented with 20 ng/mL epidermal growth fac-
tor, 0.01 mg/mL insulin, 500 ng/mL hydrocortisone, 5%
heat-inactivated HS, 100 IU/mL penicillin and 100 μg
streptomycin. All the cell lines were grown at 37°C in an
atmosphere containing 5% CO2 and 95% air.
Gli1-specific shRNA inhibition
To knock down Gli1 expression, shRNA targeting Gli1
expressed in the pSingle vector was prepared as de-
scribed previously [37]. Cells were grown in culture
dishes until they reached 75% confluence, at which point
they were transfected for 24 h with pSingle-shRNA spe-
cific to Gli1 using the Lipofectamine 2000 transfection
reagent according to the manufacturer’s instructions.
The tight on/off regulation of the pSingle vector sys-
tem and coordinate inactivation of the target gene was
mediated using doxycycline (Dox). Expression of the
shRNA in the absence of induction was extremely low
and prevented unwanted suppression of the target gene.
When Dox was added to the culture medium, transcrip-
tional suppression was relieved, permitting the shRNA
to be transcribed. After transfection, cells were trypsi-
nized, collected and subjected to various experiments.Real-time RT-PCR
Total RNA was extracted from different cell lines using
the TRIzol reagent. Quantitative determination of RNA
levels was performed in triplicate in three independent
experiments. Real-time PCR and data collection were per-
formed on the ABI PRISM 7900HT sequence detection
system (Applied Biosystems, Foster City, CA, USA). The
housekeeping gene GAPDH was used as an internal con-
trol to normalize the expression levels of different genes.
Quantification of the relative expression of target genes
was performed using the ΔΔCt method. The following
gene-specific primers were used: ERα, forward 5′-AGA
TGG TCA GTG CCT TGT TGG-3′ and reverse 5′-CCA
AGA GCA AGT TAG GAG CAA ACA G-3′; Shh, for-
ward 5′-GTG TAC TAC GAG TCC AAG GCA C-3′ and
reverse 5′-AGG AAG TCG CTG TAG AGC AGC-3′;
Gli1, forward 5′-GCG ATC TGT GAT GGA TGA GAT
TCC C-3′ and reverse 5′-TGC CTT GTA CCC TCC
TCC CGA A-3′; SOX2, forward 5′-GCT GTA TGG CTG
CTG CAC TTC A-3′ and reverse 5′-GCA CAC GCA
CCC AGC ACT GT-3′; Nanog, forward 5′-AAT ACC
TCA GCC TCC AGC AGA TG-3′ and reverse 5′-TGC
GTC ACA CCA TTG CTA TTC TTC-3′; Bmi-1, forward
5′-GAC CAC TAC TGA ATA TAA GG-3′ and reverse
5′-CAT TTG TCA GTC CAT CTC TC-3′; ALDH1, for-
ward 5′-GTT AGC TGA TGC CGA CTT GG-3′ and re-
verse 5′-CCC ACT CTC AAT GAG GTC AAG-3′; Ptch1,
forward 5′-TCG CTC TGG AGC AGA TTT CC-3′ and
reverse 5′-TCT CGA GGT TCG CTG CTT TT −3′; and
GAPDH, forward 5′-CAA GGT CAT CCA TGA CAA
CTT TG-3′ and reverse 5′-GTC CAC CAC CCT GTT
GCT GTA G-3′.
Western blot analysis
Cells were lysed in lysis buffer (1% Triton X-100,
150 mM NaCl, 10 mM Tris–HCl [pH 7.4], 1 mM EDTA,
1 mM EGTA, 2 mM NaF, 1 mM sodium orthovanadate,
10 μg/mL leupeptin, 10 μg/mL pepstatin, 10 μg/mL
aprotinin, 10 μg/mL E 64 and 1 mM Pefabloc; EMD).
Protein concentrations were determined using an En-
hanced BCA Protein Assay Kit (Beyotime Institute
of Biotechnology, Jiangsu, China) and then boiled for
5 min. Protein samples (30 μg) were separated by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidene difluoride
(PVDF) membranes (Millipore Corporation, Billerica,
MA, USA). Membranes were rinsed in Tris-buffered
saline containing Tween 20 (TBST), blocked with 5% bo-
vine serum albumin (BSA) for 2 h at room temperature,
and incubated with the primary antibody at 4°C overnight.
The membranes were then rinsed and incubated in
peroxidase-conjugated secondary antibodies for 1 h at
room temperature. After washing, proteins were detected
using enhanced chemiluminescence (ECL) (Millipore
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with anti-β-actin mouse monoclonal antibodies to confirm
equal loading of samples.Confocal immunofluorescence microscopy
Cell lines were plated on culture slides (Costar, Manassas,
VA, USA). After 4 days, cells were rinsed with phosphate-
buffered saline (PBS), fixed with 4% paraformaldehyde in
PBS, and permeabilized using 0.5% Triton X-100. Cells
were then blocked for 30 min in 10% BSA (Sigma Aldrich,
St. Louis, MO, USA) in PBS and then incubated with
primary monoclonal antibodies in 10% BSA overnight at
4°C. After three washes in PBS, slides were incubated for
1 h in the dark with FITC-conjugated secondary goat anti-
mouse or goat anti-rabbit antibodies (Invitrogen). After
three additional washes, slides were stained with 4-,6-dia-
midino-2-phenylindole (DAPI; Sigma Aldrich) for 5 min
to visualize the nuclei and examined using a Carl Zeiss
confocal imaging system (LSM 780; Carl Zeiss, Jena,
Germany).Fluorescence-activated cell sorting (FACS) analysis
Anti-CD44-APC and anti-CD24-PE antibodies used for
FACS analysis were obtained from Biolegend (San Diego,
CA, USA). Briefly, for each cell line, 1 × 106 cells were ali-
quoted into two tubes; tube 1 was stained with IgG isotype
controls for APC and PE, and tube 2 was stained with
anti-CD44-APC and anti-CD24-PE antibodies. Cells were
incubated with the appropriate antibodies for 30 min on
ice and then washed with PBS. Cells were analyzed using
a FACSCalibur flow cytometer (BD Biosciences); each
sample required 10,000 cells for analysis.Cell cycle assays
Aliquots of 1 × 105 cells were collected using trypsiniza-
tion and treated with 50 μg/mL DNase-free RNase and
20 μg/mL propidium iodide (PI) following the manufac-
turer’s instructions. Cells were analyzed using an FC500
instrument (Beckman Coulter, Brea, CA) with MultiCycle
for Windows software (Beckman Coulter) for detailed cell
cycle status.Apoptosis analysis
Apoptosis was determined using the Annexin V-FITC
Apoptosis Detection Kit (BD Biosciences Pharmingen,
San Diego, CA, USA) according to the manufacturer’s in-
structions. Briefly, cells were detached and resuspended in
100 μL binding buffer containing FITC-Annexin V and PI.
After incubation for 15 min at room temperature in the
dark, cells were analyzed using an FC500 instrument
(Beckman Coulter). Annexin V-positive cells were classi-
fied as apoptotic.Mammosphere culture
Mammosphere culture was performed as described by
Dontu et al. with slight modifications [38]. Single-cell sus-
pensions were plated in ultralow attachment 96-well plates
(Costar) at different densities of viable cells. Cells were
grown in serum-free mammary epithelial growth me-
dium (MEGM), supplemented with 1:50 B27 (Invitrogen),
20 ng/mL epithelial growth factor (EGF), 20 ng/mL basic
fibroblast growth factor (bFGF; BD) and 10 μg/mL heparin
(Sigma). The number of spheroids was counted after
7–10 days. For in vitro propagation, primary spheres were
collected, dissociated into single-cell suspensions and
plated in ultralow attachment 96-well plates. The se-
condary number of spheroids was counted 14 days after
plating.
Colony formation assay
Cells were seeded in triplicate at 500 cells/6-cm dish in
complete medium. After 3 weeks of growth, cells were
fixed and stained with crystal violet (0.1% w/v in 20 nM
4-morpholinepropanesulfonic acid; Sigma), and visible
colonies were counted according to the number of cells
in each colony. All experiments were repeated at least
three times. Plating efficiency was determined as the
number of colonies formed divided by the total number
of cells plated.
Wound scratch migration assay
Cells were seeded in 6-cm culture dishes, and cell
monolayers were wounded by scratching with sterile
plastic 200-μL micropipette tips and photographed using
phase-contrast microscopy immediately following and
48 h after wounding. Migration assays were indepen-
dently performed in triplicate. The migration distance of
each cell was measured after the photographs were con-
verted to Photoshop files.
Matrigel invasion assay
Invasion of cells was measured in Matrigel (BD)-coated
transwell inserts (6.5 mm, Costar) containing polycar-
bonate filters with 8-μm pores, as detailed previously [39].
Inserts were coated with 50 μL of 1 mg/mL Matrigel
matrix according to the manufacturer’s recommendations.
A total of 2 × 105 cells in 200 μL serum-free medium were
plated in the upper chamber, and 600 μL of medium con-
taining 10% FBS was added to the lower chamber. After
24 h incubation, top cells (noninvasive) were removed,
and bottom cells (invasive) were counted. Cells that in-
vaded to the lower surface of the membrane were fixed in
4% paraformaldehyde and stained with 0.5% crystal violet.
For each membrane, five random fields were counted
at 10× magnification. Data were presented as the mean ±
SD from three independent experiments performed in
triplicate.
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A chromatin immunoprecipitation kit (Cat. 17–371) was
purchased from Millipore and ChIP experiments were
carried out essentially as described (27). Immunopre-
cipitated DNA was analyzed on an ABI PRISM 7900HT
sequence detection system. Primers used for detection of
promoters following ChIP are located at −653 to −472 bp
(1), −297 to −116 bp (2) and +167 to +359 bp (3) of the
Gli1 promoter.
Tissue microarrays and immunohistochemical analyses
Tissue microarrays of breast samples (BC081116a) were
from Alenabio (Xian, China). The manufacturer provided
clinical and pathological information. Immunostaining
was performed using the avidin-biotin-peroxidase com-
plex method (UltrasensitiveTM, MaiXin, Fuzhou, China).
Sections were deparaffinized in xylene, rehydrated in a
graded series of alcohols and then boiled in 0.01 M citrate
buffer (pH 6.0) for 2 min in an autoclave. Hydrogen per-
oxide (0.3%) was applied to block endogenous peroxide
activity, and sections were incubated with normal goat
serum to reduce nonspecific binding. Tissue sections were
incubated with rabbit polyclonal anti-Gli1 antibodies
(1:100 dilution), mouse monoclonal anti-ER antibodies
(1:50 dilution) or mouse monoclonal anti-ALDH1 anti-
bodies (1:100 dilution). Staining for these antibodies was
performed at room temperature for 2 h. Biotinylated goat
anti-mouse serum IgG was used as a secondary antibody.
After washing, sections were incubated with streptavidin-
biotin conjugated with horseradish peroxidase and the
peroxidase reaction was developed with 3,30-diamino-
benzidine tetrahydrochloride. Two independent, blinded
investigators examined the slides randomly. Five views
were examined per slide and 100 cells were observed per
view at 400× magnification.
Statistical analysis
Data were described as the mean ± SD. Associations bet-
ween protein expression levels in the breast tissue micro-
array were assessed using Spearman’s rank correlation
test. Comparisons between different groups were carried
out using the Student’s two-tailed t-test. The limit of sta-
tistical significance was set at a P-value <0.05. Statistical
analysis was performed using SPSS/Win11.0 software
(SPSS, Inc., Chicago, IL, USA).
Additional files
Additional file 1: Figure S1. Estrogen promoted the expression of Gli1
and CSCs in HCC1428 cells. (A & B) Western blotting was used to detect
Gli1 in HCC1428 (A) and BT549 (B) cells treated with 10 nM estrogen (E2)
with or without 1 μM 4-hydroxy tamoxifen (4OHT) for 4 days. β-Actin
was used as a loading control. (C) HCC1428 cells were transfected with
control shRNA (shVEC), shGli1-1, or shGli1-2 in the absence or presence of
E2. Gli1 protein levels were analyzed by western blotting, and β-actinlevels were measured as a loading control. (D) HCC1428 cells were
treated with 10 nM E2 or ETOH (control) and transfected with shGli1-1,
shGli1-2, or shVEC. After 4 days, cells were stained with anti-CD44-APC
and anti-CD24-PE antibodies, and CD44+/CD24-/low subpopulations were
examined by flow cytometry. (E) Histograms illustrating the percentage of
CD44+/CD24-/low subpopulations. All data correspond to the mean ± SD of
three independent experiments. **, ## indicate significantly different from
the control, p < 0.001.
Additional file 2: Figure S2. Effects of Shh on Ptch1 and Gli1 mRNA
expression in breast cancer cells. Shh was added at the specified levels
to serum-starved breast cancer cells for 24 h, after which total RNA was
extracted and subjected to qRT-PCR analysis for Ptch1 and Gli1 mRNAs
expression levels. qRT-PCR was used to detect Ptch1 in MCF7 (A), HCC1428
(B), MDA-MB-231 (C), and BT549 (D). qRT-PCR was used to detect Gli1 in
MCF7 (E), HCC1428 (F), MDA-MB-231 (G), and BT549 (H). All data correspond
to the mean ± SD of three independent experiments. *indicate significantly
different from the control, p < 0.05. **indicate significantly different from the
control, p < 0.01.
Additional file 3: Figure S3. Effects of E2 on the cell cycle and
apoptosis of shVEC- and shGli1-transfected MCF-7 cells. MCF-7 cells
were transfected with control shRNA (shVEC), shGli1-1, or shGli1-2 in
the absence or presence of E2 for 4 days. The cells were stained with
propidium iodide and Annexin V. The rate of apoptosis (A & B) and
distribution of the cell cycle (C) were determined using flow cytometry.
Additional file 4: Figure S4. E2 enhanced the invasiveness of HCC1428
cells via Gli1. (A) Representative images of wounds at 0 and 48 h in the
presence ETOH or E2. (B) Histograms illustrating relative wound widths at 0
and 48 h. The migration distance of each cell was measured after the
photographs were converted to Photoshop files. (C) Matrigel invasion assay.
HCC1428 cells were seeded into Matrigel-coated invasion chambers and
treated with ETOH or E2 for 48 h. Representative images of stained cells
are shown. Magnification, 100×. (D) The number of migrated cells was
quantified by counting cells from 10 random fields. Data are representative
of three independent experiments. Bars represent the means ± SEs of three
experiments (**, ##: P < 0.01).
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